CLN - FRM - 18 PAYMENT INFORMATION FOR ADCV AUTHOR: Kelly Balsom Uncontrolled when printed Page 1 of 3 Active Date: 23 - Feb - 2021 Version: 1 1. ADCV ADMINISTRATION SCHEDULE The Autologous Dendritic Cell Vaccine (ADCV) administration schedule will be determined by the treating physician. An indication of timing would be: Induction Phase 3 doses during Month 1 at Days 0, 10 and 20 Booster Phase 3 additional doses during Year 1 at Months 2, 4 and 8 Maintenance Phase Additional doses twice per year, starting at Month 12 until all doses have been administered 2. COST FOR MANUFACTURING 6 DOSES FOR YEAR 1 OF TREATMENT Total of £150,000 (in 2 sta ges) to cover the one - time upfront manufacturing of the personalised ADCV and 6 doses for Year 1 of treatment. The invoices are sent by Advent Bioservices and all payments must be made in advance. 2.1. First Stage of Production (processing of tumour tissue into lysate): £50,000 is paid before the tumour tissue processing begins. Refund Policy − If the tumo u r tissue processing does not produce enough lysate (protein extract) to enable proceeding to the next stage of the manufacture of an ADCV, there will be a refund of £25,000 (half of the payment) and no further processing will occur. − However, if the tumo u r tissue processing does produ ce enough lysate to enable proceeding to the next stage of manufacturing an ADCV, and the patient chooses not to proceed or is unable (for health reasons or otherwise) to proceed, there will be no refund as the Company will have incurred the costs to produ ce the lysate. 2.2. Second Stage of Production (manufacturing the finished vaccine): £100,000 is paid after there is confirmation of sufficient tumour lysate from the tumour tissue processing and before the medical/vein assessment and leukapheresis. Refund Poli cy − If fewer than 3 doses (i.e., 1 or 2 doses) of ADCV are produced, there will be a refund of £50,000 (half of the payment) to the patient. − If no usable doses are produced, there will be a refund of £100,000 (the full second payment). − If 3 or more doses a re produced and the patient chooses not to proceed or is unable (for health reasons or otherwise) to proceed, there will be no refund as the Company will have incurred the costs to manufacture the vaccine. CLN - FRM - 18 PAYMENT INFORMATION FOR ADCV AUTHOR: Kelly Balsom Uncontrolled when printed Page 2 of 3 Active Date: 23 - Feb - 2021 Version: 1 3. COST FOR REPEAT MANUFACTURING If a second manufa cturing cycle is required (fewer than 3 doses are produced in the initial manufacturing process) and sufficient lysate remains available to enable a second manufacturing cycle, a patient may choose to undergo a repeat medical/vein assessment and leukaphere sis to repeat the manufacturing process and produce more doses of ADCV. The price and terms will be the same as for the first manufacturing process ( £100,000 ). Refund Policy − Same as the first manufacturing process set forth above. 4. COST FOR ONGOING (TWICE PER YEAR) MAINTENANCE DOSES Each semi - annual maintenance dose: £25,000 which is paid prior to administration of each dose. Refund Policy − If a patient has paid for a maintenance dose, and it is not released for administration to the patient for any r eason, or the patient is unable to receive it, the patient will be eligible for a refund of the payment made for that Maintenance Dose, and that refund will be the patient’s sole recourse. 5. ADDITIONAL FEES 5.1. Consultations (including administration) with a Ph ysician participating in the UK Specials Program The consultation and administration fees are paid directly to the physician. 5.2. Courier Shipping Fees − Transport of frozen tumour tissue to Advent Bioservices to begin the tumour lysate production: Cost varies d epending on where the frozen tumour tissue is stored. This fee is payable prior to the first administration of the vaccine. − Transport of the leukapheresis blood product to begin ADCV manufacture: Cost varies depending on where the leukapheresis is taking p lace and is payable prior to administration of the first dose. − Transport of ADCV: Each dose of ADCV is shipped via special courier in a liquid nitrogen shipper at - 150 O C to the place of administration (usually the UK physician’s clinic). It is payable prio r to administration of each dose. 5.3. Medical/Vein Assessment and Leukapheresis The cost of the medical/vein assessment and leukapheresis and any additional charges that may occur will be communicated by the physician and paid directly to the apheresis centre. 5.4. VAT We are not currently required to charge the 20% VAT tax on the ADCV. However, if this situation changes in the future, and we must charge VAT, the patient will be invoiced and responsible in full for the VAT payment. CLN - FRM - 18 PAYMENT INFORMATION FOR ADCV AUTHOR: Kelly Balsom Uncontrolled when printed Page 3 of 3 Active Date: 23 - Feb - 2021 Version: 1 6. PRODUCT AND TREATMENT POLICIES 6.1. Treatment Schedule Each dose of ADCV will be released to the physician for administration to the patient only in accordance with a treatment schedule that has been established based upon clinical trial experience. 6.2. Product Release Release of ADCV d oses may be stopped at any time for regulatory reasons, medical reasons or other reasons in the sole determination of the treating physician and/or Advent Bioservices. 6.3. Ownership and Control of ADCV Doses All ADCV doses that have been produced but have not been released for administration to a patient are not the property of the patient, and the patient expressly acknowledges that he or she has no right to require release of any ADCV dose. 7. DECLARATION By signing this document, I acknowledge that I have bee n informed of all of the fees chargeable by Advent Bioservices, including but not limited to the first and second stage of manufacturing, repeat manufacturing, maintenance doses and courier charges. Patient Full Name (printed): Patient Signature: Signature of Patient’s Representative (if applicable): Relationship to Patient (if applicable): Date of Declaration (dd - mmm - yyyy):